Literature DB >> 1617074

Enterococcal endocarditis.

D W Megran1.   

Abstract

Enterococci, most often Enterococcus faecalis, cause 5%-20% of cases of infective endocarditis (IE). Enterococcal IE is usually a disease of older men, and the most frequent source of infection is the genitourinary tract. In cases of enterococcal IE, both normal and previously damaged valves can be involved. The disease most commonly presents in a subacute fashion; clinical and laboratory features are similar to those observed with IE caused by other pathogens. Diagnosis is based on the presence of clinical criteria of IE in association with positive blood cultures. Optimal therapy entails the parenteral use of a cell wall-active agent (penicillin G, ampicillin, or vancomycin) in combination with streptomycin or gentamicin in cases caused by enterococcal strains with high-level resistance to streptomycin. A 4-week treatment course may be adequate in many cases. In patients with streptomycin-resistant strains, mitral valve disease, illness of greater than 3 months' duration, and/or relapse after previous therapy, a 6-week treatment course should probably be administered. With standard treatment and the appropriate use of valve replacement, a cure rate of approximately 85% can be expected.

Entities:  

Mesh:

Year:  1992        PMID: 1617074     DOI: 10.1093/clinids/15.1.63

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  39 in total

1.  Enterococcal endocarditis: can we win the war?

Authors:  Jose M Munita; Cesar A Arias; Barbara E Murray
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

Review 2.  Relationships between enterococcal virulence and antimicrobial resistance.

Authors:  L M Mundy; D F Sahm; M Gilmore
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

3.  Survival of Enterococcus faecalis in mouse peritoneal macrophages.

Authors:  C R Gentry-Weeks; R Karkhoff-Schweizer; A Pikis; M Estay; J M Keith
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

4.  Pathogenic Mechanisms of Enterococcal Endocarditis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

Review 5.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

6.  Comparative study of bacteremias caused by Enterococcus spp. with and without high-level resistance to gentamicin. The Grupo Andaluz para el estudio de las Enfermedades Infecciosas.

Authors:  F J Caballero-Granado; J M Cisneros; R Luque; M Torres-Tortosa; F Gamboa; F Díez; J L Villanueva; R Pérez-Cano; J Pasquau; D Merino; A Menchero; D Mora; M A López-Ruz; A Vergara
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

7.  Pili prove pertinent to enterococcal endocarditis.

Authors:  Jonathan M Budzik; Olaf Schneewind
Journal:  J Clin Invest       Date:  2006-10       Impact factor: 14.808

8.  Endocarditis and biofilm-associated pili of Enterococcus faecalis.

Authors:  Sreedhar R Nallapareddy; Kavindra V Singh; Jouko Sillanpää; Danielle A Garsin; Magnus Höök; Stanley L Erlandsen; Barbara E Murray
Journal:  J Clin Invest       Date:  2006-10       Impact factor: 14.808

9.  Multiple functional domains of Enterococcus faecalis aggregation substance Asc10 contribute to endocarditis virulence.

Authors:  Olivia N Chuang; Patrick M Schlievert; Carol L Wells; Dawn A Manias; Timothy J Tripp; Gary M Dunny
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

10.  Virulence factors and in vitro adherence of Enterococcus strains to urinary catheters.

Authors:  E Dworniczek; K Kuzko; E Mróz; Ł Wojciech; R Adamski; B Sobieszczańska; A Seniuk
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.